Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
Mon, 21.10.2024
Friedrich Vorwerk Group SE
Disclosure of inside information acc. to Article 17 MAR
FRIEDRICH VORWERK grows by 32% in the third quarter to €145m in revenues with an EBITDA margin of 17.5% and raises its 2024 forecast to €430-460m in revenues with an EBITDA margin of 14-15 %
Tostedt, 21 October 2024 - FRIEDRICH VORWERK Group SE (ISIN DE000A255F11), a leading provider of ener [ … ]
Mon, 21.10.2024
ARYZTA AG
Ad hoc announcement pursuant to article 53 LR
PDF Downloadlink
About ARYZTA
ARYZTA AG (‘ARYZTA’) is an international bakery company with a leadership position
in convenience bakery. ARYZTA is based in Schlieren, Switzerland, with operations in
Europe, Asia, Australia and New Zealand. ARYZTA is listed on the SIX Swiss Exchange
(SIX: ARYN)
End of In [ … ]
Mon, 21.10.2024
Relief Therapeutics Holding SA
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
GENEVA (OCT. 21, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, un [ … ]
Mon, 21.10.2024
HBM Healthcare Investments AG
Profit of CHF 23 million
NAV up by 1.5 percent and share price up by 1.7 percent
Private as well as public portfolio companies contribute to earnings
Unfavourable currency movements impact performance by almost 5 percent
Successful first half – currency effects impact performance
HBM Healthcare Investments generated a profit of CHF 23 milli [ … ]
Mon, 21.10.2024
HBM Healthcare Investments AG
Profit of CHF 23 million
NAV up by 1.5 percent and share price up by 1.7 percent
Private as well as public portfolio companies contribute to earnings
Unfavourable currency movements impact performance by almost 5 percent
Successful first half – currency effects impact performance
HBM Healthcare Investments generated a profit of CHF 23 milli [ … ]
Fri, 18.10.2024
aap Implantate AG
aap Implantate AG (the “Company”) announces with reference to the ad hoc release published on October 15, 2024 at 11:25 p.m. regarding a possible cyberattack that the company's IT systems are being restarted step by step. Production was resumed after a short interruption and was almost unaffected. The ad hoc announcement on October 15, 2024 was dir [ … ]
Fri, 18.10.2024
Pentixapharm Holding AG
Würzburg and Berlin, Germany, October 18, 2024 - The European Medicine Agency (EMA) has granted PRIME Status to Pentixapharm’s lead candidate Ga68-PentixaFor, thereby granting an early and proactive support for the development of the radiodiagnostic and the possibility of an accelerated approval. The benefits of PRIME status include an early appoin [ … ]
Fri, 18.10.2024
flatexDEGIRO AG
flatexDEGIRO AG: Mandate of BaFin’s special commissioner terminated
The mandate of the BaFin’s special commissioner at flatexDEGIRO Bank AG (the “Company”) was terminated on September 30, 2024, following the successful elimination of the serious deficiencies identified in the 2022 special audit by the Company and a positive review by the special co [ … ]
Fri, 18.10.2024
AMADEUS FIRE AG
Adjusted guidance of operating EBITA for full-year 2024
Frankfurt/Main, 18thOctober 2024
The growing pessimism in the German economy over recent months, along with the resulting hesitancy in placing orders, has had a noticeable impact on the Amadeus Fire Group’s results for the first nine months of 2024. The Management Board expects no market c [ … ]
Fri, 18.10.2024
H&R GmbH & Co. KGaA
Insider information pursuant to Article 17 of the Market Abuse Regulation [MAR]
H&R GmbH & Co. KGaA: Preliminary Figures for nine months of 2024
Sales revenues exceed EUR 1.0 billion once again
EBITDA at previous year's level of EUR 65.9 million (first nine months of 2023: EUR 66.6 million)
Earnings stabilization in the third quarter [ … ]